Praxis Precision Medicines, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
PRAX$337.59+1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Comprehensive Loss for
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Amounts in thousands)
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Net loss | $(94,234) | $(73,934) | $(270,515) | $(214,357) |
| Change in unrealized (loss) gain on marketable securities, net of tax | (3,055) | 105 | (6,290) | (154) |
| Comprehensive loss | $(97,289) | $(73,829) | $(276,805) | $(214,511) |
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Amounts in thousands, except share data)
| Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · Accumulated Other Comprehensive Gain (Loss) · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance at December 31, 2025 | 25,195,092 | $15 | $2,017,566 | $(1,140,008) | $563 | $878,136 |
| Stock-based compensation expense | — | — | 17,112 | — | — | 17,112 |
| Issuance of common stock from follow-on public offering, net of underwriting discounts, commissions and offering costs of $40,153 | 2,543,800 | — | 621,235 | — | — | 621,235 |
| Vesting of restricted stock units | 134,225 | — | — | — | — | — |
| Shares withheld for taxes for vesting of restricted stock units | (45,548) | — | (12,923) | — | — | (12,923) |
| Issuance of common stock upon exercise of stock options | 31,945 | — | 1,119 | — | — | 1,119 |
| Change in unrealized gain on marketable securities, net of tax | — | — | — | — | (2,157) | (2,157) |
| Net loss | — | — | — | (92,561) | — | (92,561) |
| Balance at March 31, 2026 | 27,859,514 | $15 | $2,644,109 | $(1,232,569) | $(1,594) | $1,409,961 |
| Stock-based compensation expense | — | — | 11,309 | — | — | 11,309 |
| Issuance of common stock under employee stock purchase plan | 4,817 | — | 809 | — | — | 809 |
| Vesting of restricted stock units | 4,400 | — | — | — | — | — |
| Shares withheld for taxes for vesting of restricted stock units | (1,098) | — | (310) | — | — | (310) |
| Issuance of common stock upon exercise of stock options | 48,960 | — | 4,073 | — | — | 4,073 |
| Change in unrealized loss on marketable securities, net of tax | — | — | — | — | (1,078) | (1,078) |
| Net loss | — | — | — | (83,720) | — | (83,720) |
| Balance at June 30, 2026 | 27,916,593 | $15 | $2,659,990 | $(1,316,289) | $(2,672) | $1,341,044 |
| Stock-based compensation expense | — | — | 14,891 | — | — | 14,891 |
| Vesting of restricted stock units | 4,791 | — | — | — | — | — |
| Shares withheld for taxes for vesting of restricted stock units | (1,502) | — | (493) | — | — | (493) |
| Issuance of common stock upon exercise of stock options | 28,361 | — | 1,422 | — | — | 1,422 |
| Change in unrealized loss on marketable securities, net of tax | — | — | — | — | (3,055) | (3,055) |
| Net loss | — | — | — | (94,234) | — | (94,234) |
| Balance at September 30, 2026 | 27,948,243 | $15 | $2,675,810 | $(1,410,523) | $(5,727) | $1,259,575 |
| Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · Accumulated Other Comprehensive Gain · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance at December 31, 2024 | 19,422,358 | $14 | $1,281,522 | $(836,740) | $654 | $445,450 |
| Stock-based compensation expense | — | — | 8,786 | — | — | 8,786 |
| Issuance of common stock from at-the-market public offerings, net of commission costs of $1,120 | 694,212 | — | 54,904 | — | — | 54,904 |
| Issuance of common stock from exercise of pre-funded warrants | 173,840 | — | — | — | — | — |
| Vesting of restricted stock units | 55,850 | — | — | — | — | — |
| Shares withheld for taxes for vesting of restricted stock units | (18,765) | — | (1,195) | — | — | (1,195) |
| Issuance of common stock upon exercise of stock options | 14,422 | — | 560 | — | — | 560 |
| Change in unrealized gain on marketable securities, net of tax | — | — | — | — | 5 | 5 |
| Net loss | — | — | — | (69,296) | — | (69,296) |
| Balance at March 31, 2025 | 20,341,917 | $14 | $1,344,577 | $(906,036) | $659 | $439,214 |
| Stock-based compensation expense | — | — | 7,770 | — | — | 7,770 |
| Issuance of common stock from at-the-market offerings, net of commission costs of $579 | 657,477 | — | 28,360 | — | — | 28,360 |
| Issuance of common stock from exercise of pre-funded warrants | 26,509 | — | — | — | — | — |
| Issuance of common stock under employee stock purchase plan | 9,319 | — | 294 | — | — | 294 |
| Vesting of restricted stock units | 5,860 | — | — | — | — | — |
| Shares withheld for taxes for vesting of restricted stock units | (608) | — | (23) | — | — | (23) |
| Change in unrealized gain on marketable securities, net of tax | — | — | — | — | (264) | (264) |
| Net loss | — | — | — | (71,127) | — | (71,127) |
| Balance at June 30, 2025 | 21,040,474 | $14 | $1,380,978 | $(977,163) | $395 | $404,224 |
| Stock-based compensation expense | — | — | 7,447 | — | — | 7,447 |
| Issuance of common stock from at-the-market public offerings, net of issuance and commission costs of $359 | 102,364 | — | 4,907 | — | — | 4,907 |
| Vesting of restricted stock units | 3,746 | — | — | — | — | — |
| Shares withheld for taxes for vesting of restricted stock units | (1,106) | — | (52) | — | — | (52) |
| Issuance of common stock upon exercise of stock options | 20,455 | — | 808 | — | — | 808 |
| Change in unrealized gain on marketable securities, net of tax | — | — | — | — | 105 | 105 |
| Net loss | — | — | — | (73,934) | — | (73,934) |
| Balance at September 30, 2025 | 21,165,933 | $14 | $1,394,088 | $(1,051,097) | $500 | $343,505 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.